Switzerland's Kuros Biosciences 2025 total medical device revenue rises, helped by MagnetOs growth

Kuros Biosciences AG

10/03/2026 06:16

Overview

Switzerland's bone healing tech firm reported 72% total medical device revenue growth in 2025

Company achieved first-ever net profit of USD 2.6 million

Company expects at least 35% sales growth in 2026

Outlook

Kuros expects at least 35% sales growth in 2026 with adjusted EBITDA margin around 14%

Company anticipates 2028 sales of USD 300 to 330 mln with adjusted EBITDA margin of 20%

Kuros sees growth driven by MagnetOs adoption and market penetration in U.S. and Europe

Result Drivers

MAGNETOS SALES - Direct MagnetOs sales rose by 71% to USD 143.9 mln, significantly contributing to overall revenue growth

MARKET EXPANSION - Kuros expanded into the extremities market, supported by a dedicated commercial team and clinical trials

NEW PRODUCT LAUNCHES - FDA clearance and launch of MagnetOs MIS Delivery System supported minimally invasive surgeries

Company press release: ID:nGNX3zFzYw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Total Medical Device Revenue
$146.06 mln
FY Operating Income
$8.95 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Kuros Biosciences AG is CHF36.50, about 37.3% above its March 9 closing price of CHF26.58

The stock recently traded at 78 times the next 12-month earnings vs. a P/E of 95 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)